Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Trichiconins C to preparation of respiratory syncytial virus (RSV) resistant drugs

A syncytial virus, anti-respiratory technology, applied in antiviral agents, pharmaceutical formulations, medical preparations containing active ingredients, etc.

Inactive Publication Date: 2015-07-15
THE AFFILIATED DRUM TOWER HOSPITAL MEDICAL SCHOOL OF NANJING UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In the past, there was no specific etiological treatment for RSV infection, and the treatment was mainly supportive and symptomatic. In recent years, ribavirin-specific antiviral and passive immunotherapy (immunoglobulin therapy), etc., can often achieve the goal of early etiological treatment. However, neither specific antiviral nor passive immunization methods can completely, directly and effectively kill RSV

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Trichiconins C to preparation of respiratory syncytial virus (RSV) resistant drugs
  • Application of Trichiconins C to preparation of respiratory syncytial virus (RSV) resistant drugs
  • Application of Trichiconins C to preparation of respiratory syncytial virus (RSV) resistant drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] Trichiconins C is a new skeleton compound, and its structural formula is as follows:

[0018]

[0019] The preparation of compound Trichiconins C tablet involved in the present invention:

[0020] Take 20 grams of compound Trichiconins C, add 180 grams of conventional excipients for tablet preparation, mix well, and make 1000 tablets with a conventional tablet press.

Embodiment 2

[0022] The preparation of compound Trichicorins C capsules involved in the present invention:

[0023] Get 20 grams of compound Trichiconins C, add conventional auxiliary materials such as starch 180 grams for the preparation of capsules, mix well, and pack into capsules to make 1000 tablets.

[0024] The following pharmacodynamic experiments will further illustrate its drug activity.

experiment example

[0025] Experimental Example: Study on the Effect of Compound Trichiconins C on Respiratory Syncytial Virus (RSV)

[0026] (1) Preparation of the compound Trichiconins C: the compound Trichiconins C was dissolved in cell maintenance solution (MEM containing 2% neonatal calf serum, product of GIBICO Company) for later use.

[0027] (2) Cell strains and virus strains:

[0028] Human embryonic kidney cells (HEK293, RSV virus-sensitive cells) were purchased from Clontech Corporation of the United States; respiratory syncytial virus (RSV) Long strain was quoted from China CDC Institute of Viral Diseases.

[0029] (3) Cytotoxicity assay:

[0030] The samples were serially diluted 2-fold (2 0～-5 ), then inoculated horizontally on HEK293 in 96 plate wells according to the dilution sequence, 100uL per well, and repeated 3 wells (rows A, B, C) vertically for each dilution. Control, 7-12 wells were not inoculated with cells as a blank control, observed CPE daily under a microscope, con...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of Trichiconins C to preparation of respiratory syncytial virus (RSV) resistant drugs. The compound Trichiconins C is prepared into tablets and capsules. The defect that the RSV can not be completely, directly and effectively killed by existing treatment methods is overcome. Trichiconins C has unexpected strong RSV inhibiting activity and does not have the possibility that other compounds give any enlightenment. Experiments prove that Trichiconins C has outstanding inhibiting effects on the RSV, is used for inhibiting the RSV from having the cytopathic effect (CPE) in the HEK293 cell and has IC50 of 2<-10.49> and TI of 278.23; therefore Trichiconins C has prominent substantive characteristics and obviously has outstanding progress when being used for controlling the RSV.

Description

technical field [0001] The invention relates to the application of a medicine, in particular to the application of Trichiconins C in the preparation of anti-respiratory syncytial virus medicine. Background technique [0002] RSV (Respiratory Syncytial Virus, Respiratory Syncytial Virus) mainly causes respiratory system infection. The virus is endemic and causes severe pneumonia in infants, the elderly and immunocompromised populations. It is one of the important pathogens of human upper respiratory tract infection. RSV is endemic, and winter usually has a period of high incidence of the disease. The mode of virus transmission is mainly through droplet transmission, and the direct inoculation of the virus into the nasal mucosa and eye mucosa by contaminated fingers is also an important transmission route for infection. The pathogenesis of RSV lower respiratory tract infection involves interactions between the virus and host affected cell injury, inflammation, humoral and loc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/366A61P31/14
Inventor 冯丹丹
Owner THE AFFILIATED DRUM TOWER HOSPITAL MEDICAL SCHOOL OF NANJING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com